The Role of Hypertonic Dextrose Spray as Endoscopic Topical Hemostatic Agent for Acute Non-Variceal Upper GI Bleeding
NCT ID: NCT04979273
Last Updated: 2021-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
66 participants
INTERVENTIONAL
2021-03-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparative Study of Autologous Blood Injection Versus Diluted Epinephrine in Treating Actively Bleeding Gastroduodenal Ulcers
NCT01560702
IV Glucose for Dehydration Treatment
NCT01285713
3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency
NCT04228445
Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children
NCT04654507
Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis
NCT00612014
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Group
Patients within control group will be given adrenaline 1:20.000 injection, followed by thermocoagulation or hemoclip
Adrenaline 1 Mg/mL Solution for Injection
injection of adrenaline 1:20.000, followed by thermocoagulation or hemoclip
argon plasma coagulation
Thermocoagulation
Hemoclip
Hemoclip
Dextrose group
Patients within this group will be given adrenaline 1:20.000 injection, followed by dextrose 40% spray
Dextrose 40 % in Water
injection of adrenaline 1:20.000, followed by dextrose 40% spray
Adrenaline 1 Mg/mL Solution for Injection
injection of adrenaline 1:20.000, followed by thermocoagulation or hemoclip
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dextrose 40 % in Water
injection of adrenaline 1:20.000, followed by dextrose 40% spray
Adrenaline 1 Mg/mL Solution for Injection
injection of adrenaline 1:20.000, followed by thermocoagulation or hemoclip
argon plasma coagulation
Thermocoagulation
Hemoclip
Hemoclip
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients consented to study participation
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr Cipto Mangunkusumo General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hasan Maulahela, MD
Head of Gastrointestinal Endoscopy Center FKUI-RSCM
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hasan Maulahela, MD
Role: PRINCIPAL_INVESTIGATOR
Dr Cipto Mangunkusumo General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr. Cipto Mangunkusumo General Hospital
Jakarta Pusat, DKI Jakarta, Indonesia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20-02-0130
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.